Nasdaq GlobeNewswire

CellAegis Announces Completion of Patient Enrollment in Danish Investigator Sponsored Clinical Trial Using autoRIC® Device

Del

TORONTO, May 17, 2018 (GLOBE NEWSWIRE) -- CellAegis Devices Inc. ("CellAegis" or the "Company"), a commercial-stage medical device company advancing innovative, non-invasive, safe and cost-effective solutions for acute and chronic cardiovascular conditions, today announced completion of patient enrollment in a large scale, investigator sponsored trial ("CONDI 2") to further assess the efficacy of remote ischemic conditioning ("RIC") in reducing clinical events in patients presenting with ST-segment-elevation myocardial infarction ("STEMI") and receiving point of care treatment by paramedics in an ambulance. This trial utilized CellAegis' autoRIC® (http://cellaegis.com/products/) device to deliver the RIC therapy.

CONDI 2 is a multinational, randomized, controlled, single-blind, parallel assignment clinical trial which enrolled 2,600 STEMI patients in ambulances in Denmark, Serbia, and Spain. The study was sponsored by the Aarhus University Hospital in Denmark and is designed to show the benefit of RIC versus standard of care treatment in reducing cardiac death and hospitalization for heart failure at twelve months in STEMI patients. 

Data from the CONDI 2 trial is expected to augment existing positive evidence related to the therapeutic benefits of RIC in the treatment of cardiovascular disease and procedure related kidney damage. CellAegis currently expects to report the topline results of CONDI 2 trial in mid-  2019.

Meta-analysis of multiple previous studies has shown that RIC significantly reduced infarct (dead tissue) size by 43% (Journal American Heart Association: McLeod et al 2017).  In a recent prospective trial conducted in 448 patients at Hospital de Braga in Portugal (Basic Research Cardiology: Gaspar et al 2018), RIC treatment was also shown to reduce heart failure/cardiac death events by 62% at two years. 

"The portability and ease of use of the autoRIC® device fit seamlessly into the ambulance setting," said Hans Erik Bøtker, MD, PhD, FESC, FACC, Professor of Cardiovascular Medicine and Interventional Cardiology and co-director of Department of Cardiology, Aarhus University Hospital Skejby, the principal investigator for CONDI 2. "The autoRIC's fully automated features allows emergency response professionals to deliver a novel, non-invasive therapy while focusing on other patient care needs."

"More than 2.9 million patients worldwide are hospitalized each year with an acute coronary syndrome," said Rocky Ganske, Chief Executive Officer, CellAegis.  "One-third of those patients have STEMI, which may lead to heart failure. While there has been advancement in the treatment of these patients utilizing PCI and other therapies, there is no question that significant unmet medical need remains.  This trial, with over 2,600 patients, is unprecedented in size for medical devices, and if the outcome is positive, as the company anticipates, we believe autoRIC® has the potential to change the standard of care for STEMI patients."

"This trial, in combination with a large UK hospital STEMI trial ("ERIC-PPCI") and our US FDA registration trial ("SHIELD"), is expected to definitively demonstrate whether RIC can improve outcomes for patients with STEMI or undergoing elective PCI procedures while at the same time lowering patient treatment costs. Data from these trials is expected to drive expanded adoption of the autoRIC® device in Europe followed by the U.S.," continued Mr.  Ganske.

About RIC

RIC is a noninvasive therapy that utilizes four cycles of limb occlusion and reperfusion to protect the heart and other tissue against ischemia-reperfusion injury. RIC is a promising adjunctive treatment to stenting in the prevention of ischemic-reperfusion injury and minimization of post-infarct heart failure in ST-elevation myocardial infarction ("STEMI") patients. Previous proof-of-concept clinical studies with RIC have demonstrated improvements in markers of injury, such as increased myocardial salvage and reduced infarct size as well as reduction of contrast-induced acute kidney injury, in various clinical scenarios such as heart attacks and elective cardiac procedures.

About CellAegis Devices

CellAegis Devices, headquartered in Toronto, Canada, is the world leader in automated remote ischemic conditioning. The company has patented and developed the non-invasive autoRIC® device, which delivers RIC therapy to patients with acute and chronic cardiovascular conditions. The autoRIC device® has CE Mark and Health Canada approvals for treatment during heart attacks, cardiothoracic or surgical procedures, and is currently limited to investigational use in the United States. Investigator sponsored clinical research studies for chronic conditions such as heart failure and stroke are also underway. The autoRIC® device was developed from the clinical work of clinicians and researchers at Toronto's world-renowned Hospital for Sick Children.

Forward-Looking Statements

This press release may contain forward-looking statements identified by words such as "expects", "anticipates", "will" and similar expressions, which reflect CellAegis' current expectations regarding future events. The forward-looking statements involve risks and uncertainties that could cause the Company's actual events to differ materially from those projected herein. The forward-looking statements are made as of the date of this press release and CellAegis does not undertake and is not obligated to publicly update such forward looking statements to reflect new information, subsequent events or otherwise,  except as required by law.

Contact:

Melane Sampson
Investor Relations
melane@kilmerlucas.com
1-888-545-6374

Rocky Ganske
Chief Executive Officer
rganske@cellaegisdevices.com www.cellaegis.com 




This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: CellAegis Devices Inc. via Globenewswire

Om Nasdaq GlobeNewswire

Nasdaq GlobeNewswire
Nasdaq GlobeNewswire
One Liberty Plaza - 165 Broadway
NY 10006 New York

+1 212 401 8700http://www.nasdaqomx.com

NASDAQ (NASDAQ: NDAQ) is a leading provider of trading, exchange technology, information and public company services across six continents.

Følg saker fra Nasdaq GlobeNewswire

Registrer deg med din epostadresse under for å få de nyeste sakene fra Nasdaq GlobeNewswire på epost fortløpende. Du kan melde deg av når som helst.

Siste saker fra Nasdaq GlobeNewswire

Quantenna and Telefónica Reinforce Strategic Partnership with New Portfolio of 8x8 MIMO Wi-Fi 6 Products12.12.2018 23:00Pressemelding

SAN JOSE, Calif., Dec. 12, 2018 (GLOBE NEWSWIRE) -- Quantenna Communications, Inc. (NASDAQ: QTNA) is further strengthening its strategic partnership with Telefónica. Through a long history of cooperation, the two companies have developed multiple generations of best-in-class products including gateways, repeaters and set-top boxes deployed in Europe and Latin America. Leveraging Quantenna’s 8x8 QSR10GU-AX, Telefónica is delivering a new portfolio of high-end fiber gateways and repeaters. The Wi-Fi 6 compliant QSR10GU-AX provides integrated dual-band, dual-concurrent 2.4GHz and 5GHz functionality in the same chipset, supporting up to a maximum speed of 10Gbps and 12 simultaneous streams. Thanks to its “Always-On DFS” feature, the QSR10GU-AX offers enhanced radar detection and spectrum analyzer capabilities with wide frequency range analysis. The QSR10GU-AX also supports advanced MU-MIMO, allowing for transmission to multiple devices at the same time, and providing higher throughput, inc

Improved Accuracy and Speed for Disease Research, Two Genomic Companies Integrate Kits and Software to Enable Deep Exploration of Epigenetic Data12.12.2018 21:16Pressemelding

OnRamp’s ROSALIND and Active Motif offer an improved ChIP-Seq data analysis experience for researchers with state-of-the-art dynamics track plots and advanced collaboration capabilities SAN DIEGO, Dec. 12, 2018 (GLOBE NEWSWIRE) -- OnRamp BioInformatics, a genomics company focused on scientist-friendly bioinformatics software solutions, today announced they are working with Active Motif to improve accuracies in data analysis for ChIP-Seq experiments. OnRamp’s flagship software, ROSALIND, provides a point-and-click experience to speed up and simplify the process of genomic data analysis from experiment setup to QC and interactive data visualization to interpretation. With this integration, researchers will now benefit from an optimized analysis that includes the unique characteristics of Active Motif kits and antibodies, including Unique Molecular Identifiers (UMI) and spike-in solutions. Active Motif customers will now be able to rapidly interpret their data with ROSALIND’s identificati

Markforged launches H13 tool steel for high-strength, high-temp tooling applications12.12.2018 15:00Pressemelding

New material for Metal X 3D printing system is first of many WATERTOWN, Mass., Dec. 12, 2018 (GLOBE NEWSWIRE) -- Markforged, the Boston-area 3D printer company transforming manufacturing, today announced the launch of H13 tool steel for the Metal X, the world’s leading desktop-sized metal printer with over 150 systems shipped since March 2018. The expansion into H13 will enable customers to print parts in high-strength, high-temperature applications such as metal forming tools, dies and punches, and hardened inserts for fixtures, and even injection molds with conformal cooling channels. To learn more about H13 tool steel and place an order, please visit http://markforged.com/h13 “We designed the Metal X system to change the way things are made, and the launch of H13 is the next step down that path,” said Jon Reilly, Markforged VP of product. “For manufacturers of high-volume plastic parts this is a game changer, significantly accelerating the speed at which they can bring new products

XBiotech’s Results from Phase 2 Atopic Dermatitis Study Suggest New Drug to Treat Skin Disease12.12.2018 14:30Pressemelding

Bermekimab Therapy Rapidly and Significantly Reduces Disease AUSTIN, Texas, Dec. 12, 2018 (GLOBE NEWSWIRE) -- XBiotech (NASDAQ: XBIT) announced today that its open label, proof of concept, multicenter study using bermekimab to treat patients with moderate to severe atopic dermatitis (AD) has completed and the study met all primary and secondary endpoints. Thirty eight patients in two treatment groups received a low (n=10) or high (n=28) dose of bermekimab once weekly for either a 4 or 7-week treatment regimen, respectively. Statistically significant improvement was seen for all efficacy endpoints in the high dose group; and a significant dose response for the high dose compared to low dose group was observed for key endpoints, including the Eczema Area and Severity Index (EASI), Global Individual Sign Score (GISS), Patient Oriented Eczema Measure (POEM), Hospital Anxiety and Depression Scale (HADS), and SCORing Atopic Dermatitis (SCORAD). While clinically and statistically significant

Cisco and UBS to host ESG Conference Call/Webcast for the Financial Community on 12/17/1812.12.2018 14:00Pressemelding

SAN JOSE, Calif., Dec. 12, 2018 (GLOBE NEWSWIRE) -- Cisco and UBS will host an ESG (Environmental, Social and Governance) Conference Call/Webcast for the Financial Community, at 11:00 a.m. ET/ 4:00 p.m. GMT on Monday, December 17, 2018. Kathy Mulvany, Cisco’s VP of Corporate Affairs, and Darrel Stickler, Cisco’s Environmental Sustainability Lead, will provide an overview of Cisco’s Corporate Social Responsibility (CSR) strategy, priorities and goals, and explain why Cisco’s CSR initiatives play an important role in overall shareholder value creation. The call will be hosted by John Roy, Ph.D., UBS IT Hardware, Networking & Services Analyst, and Julie Hudson, CFA, and Victoria Kalb, UBS Global ESG & Sustainability Analysts. Interested parties can participate by dialing toll-free: 800 694 5649 or international: +1 303 223 2687, Code: 21910788, or listening to the webcast at investor.cisco.com. Further information and Cisco’s 2018 CSR Report can be found at csr.cisco.com About Cisco Cisco

Standard Lithium Makes First Pilot-Scale High Purity Lithium Carbonate and Commissions Crystallisation Pilot Prototype12.12.2018 09:01Pressemelding

VANCOUVER, British Columbia, Dec. 12, 2018 (GLOBE NEWSWIRE) -- Standard Lithium Ltd. (“Standard Lithium” or the “Company”) (TSXV: SLL) (OTC-Nasdaq Intl. Designation: STLHF) (FRA: S5L), is pleased to announce that the Company has completed the commissioning process for its prototype crystallisation pilot plant and has produced its first quantity of high purity (>99.1%) lithium carbonate. The Company, via its technology partners, is currently designing and fabricating both halves of its full-scale Pilot Plant; the Lithium Extraction Pilot Plant is being designed and built by Zeton Inc. in Burlington, Ontario, Canada; the Lithium Carbonate Crystallisation Pilot Plant is being designed and built by Saltworks Technologies Inc., at their facility in Richmond, British Columbia, Canada. Both parts of the Pilot Plant are based on Standard Lithium’s proprietary technology. The newly-constructed crystallisation pilot prototype was operated using a relatively ‘impure’ feed solution similar to, but

I vårt presserom finner du alle våre siste saker, kontaktpersoner, bilder, dokumenter og annen relevant informasjon om oss.

Besøk vårt presserom